Halsa Pharmaceuticals, Inc. is a start-up biotechnology company developing therapeutics for the treatment of obesity and other metabolic diseases.

Halsa Pharmaceuticals has achieved exclusive patent rights to a natural material that, when injected by a physician into an obese patient, will cause immediate and substantial depletion of body fat.   Respected organizations provide significant evidence that validates the technology.

Halsa has assembled the management team, advisory board, and the industrial and academic alliances in order to facilitate commercialization of this anti-obesity therapeutic; the company has performed detailed planning with respect to critical paths to commercialization, such as manufacturing and preclinical trial protocols, has raised capital, and is executing on its plan.